Kuros Biosciences AG
SIX: KURN.SW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Swiss Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Christopher T. Fair
- Employees
- 122
- Headquarters
- Schlieren, Switzerland
- IPO year
- 2002
- Market cap
- CHF 789.8M
- Website
- https://www.kuros.ch
Loading KURN…
Loading profile data…Frequently asked questions about KURN
What does Kuros Biosciences AG (KURN.SW) do?
Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline...
Where does KURN.SW trade?
Kuros Biosciences AG (KURN.SW) trades on the Swiss Exchange.
What sector is KURN.SW in?
Kuros Biosciences AG (KURN.SW) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Kuros Biosciences AG?
Christopher T. Fair is the chief executive officer of Kuros Biosciences AG (KURN.SW).
Where is Kuros Biosciences AG headquartered?
Kuros Biosciences AG is headquartered in Switzerland.
Does KURN.SW pay a dividend?
Kuros Biosciences AG (KURN.SW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did KURN.SW go public?
Kuros Biosciences AG (KURN.SW) completed its initial public offering in 2002.